MedTrace Logo

Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease

NCT06839820 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-28

No results posted yet for this study

Summary

OBJECTIVES OF THE STUDY

1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min.
2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min.
3. Investigate resource use in terms of total length of stay and use of nursing resources.

Conditions

  • Infliximab
  • Infusion
  • IBD (Inflammatory Bowel Disease)
  • Patient Satisfaction

Interventions

OTHER

Infusion rate of infliximab

Infusion reactions of infliximab is compared between 30 and 60 minutes infliximab infusion-rates.

Sponsors & Collaborators

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Akershus University Hospital REK comittee · Akerhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Norway

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06839820 on ClinicalTrials.gov